The MHRA, a UK Government regulator, has granted Symbiosis an MIA (IMP) license to manufacture sterile liquid, lyophilized, conventional, cytotoxic and biological drugs for biotechnology company clients around the world.
Symbiosis founder and chief executive Colin MacKay said Symbiosis has built, qualified and licensed its new manufacturing facility within a matter of months.
"We have an outstanding track record of helping our clients meet their clinical trial deadlines,” MacKay added.
”This increases the value of that particular pharmaceutical asset, which in turn increases the probability of the client successfully raising crucial further investment.
"Our intention is to be both the fastest, and the best, small-scale sterile fill/finish company in the world."
Symbiosis manufacturing facility has two manufacturing suites, out of which one will be used to handle cytotoxic and highly potent pharmaceuticals.